Actively Recruiting
Effects on Cardiometabolic Risk from Short-term Stopping of Hypoglossal Nerve Stimulation Therapy in Adults with Obstructive Sleep Apnea
Led by Columbia University · Updated on 2025-07-10
60
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of stopping hypoglossal nerve stimulation HGNS therapy on heart and metabolism-related health in adults with obstructive sleep apnea OSA. This implantable therapy is designed to treat OSA, and the study aims to see how temporarily turning off the therapy impacts risks for medical problems linked to OSA. The study is interventional and randomized, focusing on short-term changes when HGNS is stopped. Participants will already have an HGNS device implanted and stabilized at a therapeutic voltage confirmed by overnight sleep study. The study has two groups one continues HGNS therapy at the therapeutic voltage representing their baseline, and the other turns off the HGNS therapy for 2 to 4 weeks to mimic untreated OSA. This crossover allows comparison of the bodys response with and without active stimulation. Throughout the study, participants will be monitored for energy expenditure and hypoxic burden during the last two weeks of each phase HGNS-on or HGNS-off. Insulin resistance will also be measured at the end of each phase. The study involves careful tracking of these health measures while participants adhere to the assigned therapy status. Total participation duration covers both phases, enabling researchers to assess the short-term cardiometabolic effects of stopping HGNS therapy.
CONDITIONS
Brief Title
Cardiometabolic Risk Effects of Short-term Cessation of Neurostimulation Therapy
Research Team
O
Otolaryngology Research Group
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here